Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. / Pedersen-Bjergaard, J.; Specht, L.; Larsen, S.O.; Ersboll, J.; Struck, J.; Hansen, M.M.; Hansen, H.H.; Nissen, N.I.
In: Lancet, Vol. 2, No. 8550, 1987, p. 83-88.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy
AU - Pedersen-Bjergaard, J.
AU - Specht, L.
AU - Larsen, S.O.
AU - Ersboll, J.
AU - Struck, J.
AU - Hansen, M.M.
AU - Hansen, H.H.
AU - Nissen, N.I.
N1 - DA - 19870812IS - 0140-6736 (Print)LA - engPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Alkylating Agents)RN - 50-18-0 (Cyclophosphamide)SB - AIMSB - IM
PY - 1987
Y1 - 1987
N2 - 391 patients treated intensively for Hodgkin's disease were followed for up to 15 years to evaluate the risk of therapy-related acute non-lymphocytic leukaemia (t-ANLL) and preleukaemia. Only two independent factors, patient age and cumulative dose of alkylating agents, were related to the risk of t-ANLL. The hazard rate of t-ANLL was roughly proportional to the square of patient age and to the total cumulative dose of alkylating agents. In 320 patients treated with alkylating agents the cumulative risk of t-ANLL increased steadily from 1 year after the start of treatment and reached 13.0% (SE 3.0) at 10 years after which time there were no further cases. Calculated from cessation of therapy with alkylating agents, however, the cumulative risk curve increased steeply during the first 1-2 years then gradually levelled out and no new cases were observed beyond 7 years. With a 15-year follow-up the general risk of solid tumours was not increased.
AB - 391 patients treated intensively for Hodgkin's disease were followed for up to 15 years to evaluate the risk of therapy-related acute non-lymphocytic leukaemia (t-ANLL) and preleukaemia. Only two independent factors, patient age and cumulative dose of alkylating agents, were related to the risk of t-ANLL. The hazard rate of t-ANLL was roughly proportional to the square of patient age and to the total cumulative dose of alkylating agents. In 320 patients treated with alkylating agents the cumulative risk of t-ANLL increased steadily from 1 year after the start of treatment and reached 13.0% (SE 3.0) at 10 years after which time there were no further cases. Calculated from cessation of therapy with alkylating agents, however, the cumulative risk curve increased steeply during the first 1-2 years then gradually levelled out and no new cases were observed beyond 7 years. With a 15-year follow-up the general risk of solid tumours was not increased.
M3 - Journal article
VL - 2
SP - 83
EP - 88
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 8550
ER -
ID: 19371728